NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$17.48
-0.15 (-0.85 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.94
$17.67
50-Day Range
$17.48
$23.98
52-Week Range
$10.81
$37.07
Volume646,464 shs
Average Volume1.32 million shs
Market Capitalization$735.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
30 days | 90 days | 365 days | Advanced Chart
Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


G1 Therapeutics logo

About G1 Therapeutics

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

660th out of 2,218 stocks

Pharmaceutical Preparations Industry

319th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for G1 Therapeutics
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its earnings results on Wednesday, May, 5th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.09) by $0.44. The business had revenue of $14.22 million for the quarter, compared to the consensus estimate of $0.37 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 45.95% and a negative net margin of 159.11%.
View G1 Therapeutics' earnings history
.

How has G1 Therapeutics' stock price been impacted by Coronavirus?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GTHX shares have increased by 20.6% and is now trading at $17.48.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GTHX?

5 equities research analysts have issued 1-year price objectives for G1 Therapeutics' shares. Their forecasts range from $21.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $54.25 in the next year. This suggests a possible upside of 210.4% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 56, Pay $215.95k)
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 46, Pay $548.18k)
  • Dr. Mark A. Velleca, Sr. Advisor & Director (Age 57, Pay $921.86k)
  • Dr. Rajesh K. Malik, Chief Medical Officer and Sr. VP of R&D (Age 62, Pay $581.3k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 45, Pay $601.06k)
  • Ms. Soma Gupta, Chief Commercial Officer (Age 48, Pay $535.02k)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 61)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum, Chief Scientific Officer (Age 57)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 52)

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Golden Green Inc. (0.14%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics
.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was acquired by a variety of institutional investors in the last quarter, including Golden Green Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $17.48.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $735.45 million and generates $45.28 million in revenue each year. The company earns $-99,250,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 122 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

Where are G1 Therapeutics' headquarters?

G1 Therapeutics is headquartered at 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.